RxDoctor Payments Data

Wasique Narvel, MD

Family Medicine · Vineland, NJNPI 1578501615

Payments from drug & device makers

$5,412in general payments, 2019–2025

Across 375 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$953
  • AstraZeneca$945
  • Novo Nordisk$552
  • GSK$420
  • Boehringer Ingelheim$370
  • Lilly USA, LLC$207
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,29298%
  • Education$1202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,412 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$345,859
Medicare patients
648
Services billed
3,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin112$105,754
TrulicityDulaglutide49$74,191
OzempicSemaglutide54$64,142
EliquisApixaban80$50,699
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$47,880
XareltoRivaroxaban61$43,399
Bydureon BciseExenatide Microspheres46$42,748
JanuviaSitagliptin Phosphate28$35,864
LinzessLinaclotide25$26,711
RybelsusSemaglutide23$26,673
MyrbetriqMirabegron36$26,110
FarxigaDapagliflozin Propanediol35$25,359
ProliaDenosumab12$20,002
EntrestoSacubitril/Valsartan21$17,383
Synjardy XrEmpagliflozin/Metformin Hcl25$15,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$370$121,388137 claims
Novo NordiskOzempic, Rybelsus$552$90,81577 claims
Lilly USA, LLCTrulicity$207$74,19149 claims
GSKTrelegy Ellipta, Anoro Ellipta$420$63,08590 claims
MerckJanuvia, Janumet$93$51,36942 claims
PfizerEliquis$205$50,69980 claims
Johnson & JohnsonXarelto$54$43,39961 claims
AbbVieLinzess$953$26,71125 claims
Astellas Pharma US IncMyrbetriq$200$26,11036 claims
AstraZenecaFarxiga$945$25,35935 claims
AmgenProlia$83$20,00212 claims
NovartisEntresto$30$17,38321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →